摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-(hydroxy-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methyl))-7-(tert-butyldimethylsilyloxy-2H-chromen-3-yl)-5-(tertbutyldimethylsilyloxy)phenol | 554430-12-5

中文名称
——
中文别名
——
英文名称
2-(4-(hydroxy-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methyl))-7-(tert-butyldimethylsilyloxy-2H-chromen-3-yl)-5-(tertbutyldimethylsilyloxy)phenol
英文别名
5-(tert-butyl-dimethyl-silyloxy)-2-(7-(tert-butyl-dimethyl-silyloxy)-4-{hydroxy-[4-(2-piperidine-1-yl-ethoxy)-phenyl]-methyl}-2H-chromen-3-yl)-phenol;5-[tert-butyl(dimethyl)silyl]oxy-2-[7-[tert-butyl(dimethyl)silyl]oxy-4-[hydroxy-[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2H-chromen-3-yl]phenol
2-(4-(hydroxy-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methyl))-7-(tert-butyldimethylsilyloxy-2H-chromen-3-yl)-5-(tertbutyldimethylsilyloxy)phenol化学式
CAS
554430-12-5
化学式
C41H59NO6Si2
mdl
——
分子量
718.094
InChiKey
FWLWYUPTZZBXJM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    732.6±60.0 °C(Predicted)
  • 密度:
    1.097±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    10.06
  • 重原子数:
    50
  • 可旋转键数:
    13
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.51
  • 拓扑面积:
    80.6
  • 氢给体数:
    2
  • 氢受体数:
    7

SDS

SDS:51d3dba8b36d713217d79bb384926c95
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
    申请人:——
    公开号:US20040259915A1
    公开(公告)日:2004-12-23
    The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用,以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途,例如热潮红、阴道干燥、骨量减少和骨质疏松症;激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生;子宫内膜异位症、子宫肌瘤、骨关节炎,以及作为避孕剂,单独使用或与孕激素或孕激素拮抗剂联合使用。
  • Synthesis of Tetracyclic Heterocompounds as Selective Estrogen Receptor Modulators. Part 1. Process Development for Scale-up of 2,5,8-Substituted 5,11-Dihydrochromeno[4,3-<i>c</i>]chromene Derivatives
    作者:Xun Li、Michael Reuman、Ronald K. Russell、Richard Adams、Robert Ma、Sandra Beish,、Shawn Branum、Scott Youells、Jerry Roberts、Nareshkumar Jain、Ramesh Kanojia、Zhihua Sui
    DOI:10.1021/op700020f
    日期:2007.5.1
    compounds are novel selective estrogen receptor modulators (SERMs). A reproducible and nonchromatographic process was developed to prepare multihundred gram quantities of 5-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,11-dihydrochromeno[4,3-c]chromene-2,8-diyl-bis(2,2-dimethylpropanoate) (14). The overall yield of this 11-step synthesis was improved from 0.17% to 7.1% after three scale-up campaigns.
    不对称的苯并吡喃并苯并吡喃化合物是新型的选择性雌激素受体调节剂(SERM)。开发了一种可重现的非色谱方法,以制备数百克数量的5-(4-(2-(2-哌啶-1-基)乙氧基)苯基)-5,11-二氢苯并[4,3 - c ]苯二甲基-2,8 -二基-双(2,2-二甲基丙酸酯)(14)。经过三个扩大规模的推广活动后,该11步合成的总产率从0.17%提高到7.1%。
  • Novel Chromene-Derived Selective Estrogen Receptor Modulators Useful for Alleviating Hot Flushes and Vaginal Dryness
    作者:Nareshkumar Jain、Ramesh M. Kanojia、Jiayi Xu、Guo Jian-Zhong、Emmanuel Pacia、Muh-Tsann Lai、Fuyong Du、Amy Musto、George Allan、Hahn、Scott Lundeen、Zhihua Sui
    DOI:10.1021/jm060353u
    日期:2006.6.1
    A novel SERM (selective estrogen receptor modulators), 1-(R), a chromene-derived bisbenzopyran, was discovered to alleviate hot flushes and effectively increase vaginal fluidity in rats. Moreover, 1-(R) was found to have beneficial effects on plasma cholesterol and bone metabolism while maintaining antiestrogenic activity in the uterus. The biological profile of its enantiomer 1-(S) was also evaluated.
查看更多